While Japan’s Eisai had set the goal to reach 10,000 patients with Leqembi by the end of its 2024 fiscal year, which wraps up in March, only 2,000 patients in the U.S. were receiving the amyloid ...

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.

Eisai officials said the new study recruited 1,795 people with earlier Alzheimer's disease and amyloid beta in the brain. Participants received either a 10 mg per kilogram dose every two weeks ...

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month.

The subject experienced swelling and bleeding in the brain, an Eisai spokeswoman said. It wasn’t clear if the death was directly caused by the drug lecanemab in a clinical trial.

Eisai is hoping to present enough evidence to the FDA to convince regulators that the benefit of treatment with lecanemab outweighs the risks and avoid a warning on the drug’s potential label.

FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for ...

Eisai, which markets major blockbuster-in-waiting Leqembi for Alzheimer’s disease, a form of dementia, is launching Theoria technologies in Japan next April to “accelerate the development of a ...